Idian Tablet 25mg (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Il Yang Pharmaceutical Co., Ltd.
MFDS item code 202102071 · Approved 2021.03.05
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with dietary control and exercise to help manage blood sugar levels in adult patients with type 2 diabetes. It can be administered alone, and if adequate control is not achieved with monotherapy, it may be combined with metformin, pioglitazone, sulfonylureas, insulin, or DPP-4 inhibitors like linagliptin. It can also be used in patients with type 2 diabetes who have cardiovascular diseases, but in this case, it is important to refer to the precautions provided by specialists. This medicine effectively controls blood sugar across various therapeutic combinations, improving diabetes management.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. No dose adjustment is required for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. No dose adjustment is required for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age and older. Initiation of this medicine is not recommended in patients 85 years of age and older because clinical experience is limited
This medication should not be administered to certain patients. First, those with allergic reactions to the active ingredient or any component of this medication should not take it. Second, patients with type 1 diabetes or diabetic ketoacidosis should not use this medication. Third, those with severely impaired kidney function, that is, with a glomerular filtration rate of less than 30 mL/min/1.73m2 or those with end-stage renal disease or undergoing dialysis should not take this medication. Fourth, individuals with lactose intolerance, galactose intolerance, or genetic lactase deficiency should not receive this medication as it contains lactose. Patients with slightly impaired kidney function should use this medication cautiously. If the glomerular filtration rate is less than 60 mL/min/1.73m2, it is best to avoid using this medication from the start, and if already in use, dosage adjustments or discontinuation may be necessary. This medication is not used in patients with end-stage renal disease or those undergoing dialysis as efficacy cannot be expected. For patients with heart failure classified as mild to moderate (NYHA class I-II), it should be used with caution, whereas its use is not recommended for those with severe heart failure (NYHA class III-IV). When taken alongside insulin or sulfonylureas, the risk of hypoglycemia may increase, so dosage reductions of insulin or secretagogues may be necessary. Attention should be paid to adverse reactions while taking this medication. Hypoglycemia, genital infections, urinary tract infections, increased urination, decrease in fluid volume, interstitial nephritis, and others may occur. Particularly, serious metabolic acidosis known as ketoacidosis might develop, so if symptoms arise, immediate consultation with medical personnel is essential. Elderly patients, particularly those over 75 years old, are at higher risk of fluid loss, thus caution is advised. This medication can affect liver or kidney function; therefore, periodic kidney function tests are required before and during administration. Women who are pregnant are advised to avoid taking this medication, and upon confirmation of pregnancy, discontinuation of use is recommended. Breastfeeding women are advised to cease breastfeeding while taking this medication. This medication has not been established for safety and efficacy in children under 18 years of age, so it should not be used. No specific toxic symptoms have been reported in the event of overdose; however, in case of overdose, immediate consultation with a medical institution for appropriate treatment is necessary. This medication may interact with other drugs, particularly with diuretics, insulin, and sulfonylureas, thus caution is needed when co-administered. While taking this medication, patients should be careful while driving or operating machinery due to the risk of hypoglycemia. Finally, this medication should be kept out of reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in an airtight container to prevent exposure to air or moisture, and it is important to maintain storage temperatures between 1 and 30 degrees Celsius. By adhering to these storage conditions, the medication's effectiveness and safety can be well maintained.
Light yellow, oval-shaped film-coated tablet with both sides convex
10 tablets/box [10 tablets/PTP x 1], 30 tablets/box [10 tablets/PTP x 3], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 25mg
Tablet · Prescription medication
Il Yang Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.